> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher Awarded to Krystal Bio
- URL: https://www.fdaweb.com/priority-review-voucher-awarded-to-krystal-bio/
- Published: 2023-06-06T12:00:00.000Z
- Updated: 2026-09-14T18:36:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154619

*Federal Register* notice: FDA is announcing the issuance of a priority review voucher to Krystal Biotech in response to an approved rare pediatric disease product application. The qualifying product is Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with dystrophic epidermolysis bullosa. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-06-06/pdf/2023-11907.pdf?ref=fdaweb.com).